Jose Pluguez
General Practice · Davenport, FLNPI 1922158476
Payments from drug & device makers
Across 58 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$126
- Novo Nordisk$125
- AstraZeneca$120
- Amgen$104
- Boehringer Ingelheim$74
- Abbott$72
- plus $517 from 15 others
What the payments were for
- Food & beverage$1,08896%
- Gifts$504%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $126 |
| Novo Nordisk | 7 | $125 |
| AstraZeneca | 8 | $120 |
| Amgen | 6 | $104 |
| Boehringer Ingelheim | 4 | $74 |
| Abbott | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Chiesi USA, Inc. | 2 | $70 |
| Boston Scientific | 1 | $60 |
| GSK | 3 | $44 |
| Johnson & Johnson | 1 | $41 |
| Hologic Sales And Service, LLC | 1 | $34 |
| Dexcom, Inc. | 2 | $33 |
| AbbVie | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Bayer | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
How this compares
$1,138 in reported general payments places this provider in the 80th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $50,619 |
| EliquisApixaban | 34 | $27,824 |
| OzempicSemaglutide | 19 | $22,913 |
| XareltoRivaroxaban | 19 | $17,549 |
| FarxigaDapagliflozin Propanediol | 20 | $15,747 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,211 |
| LinzessLinaclotide | 11 | $5,765 |
| Atorvastatin Calcium | 315 | $3,125 |
| Rosuvastatin Calcium | 113 | $2,589 |
| Tadalafil | 12 | $2,247 |
| Lidocaine | 12 | $1,952 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,667 |
| Montelukast Sodium | 95 | $1,504 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $1,349 |
| Losartan Potassium | 162 | $1,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $74 | $50,61944 claims |
| PfizerEliquis | $18 | $27,82434 claims |
| Novo NordiskOzempic | $125 | $22,91319 claims |
| Johnson & JohnsonXarelto | $41 | $17,54919 claims |
| AstraZenecaFarxiga | $120 | $15,74720 claims |
| AbbVieLinzess, Synthroid | $30 | $6,71024 claims |
| GSKBreo Ellipta | $44 | $6,21116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,901 general practice providers in Florida.
Other general practice in Davenport
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.